


IFW



**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:

Date: June 28, 2004 Name: Carolyn Beason-Wright Signature: Carolyn Beason-Wright

**BRINKS  
HOFER  
GILSON  
& LIONE**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Appln. of: Constantin Cope, et al.  
Appln. No.: 10/813,806  
Filed: March 31, 2004  
For: BLOODLESS PERCUTANEOUS  
INSERTION SYSTEM  
Attorney Docket No: 8627/487 (PA-5391)

Examiner: Unknown  
Art Unit: 3762

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

Sir:

**Attached is/are:**

- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ Return Receipt Postcard

**Fee calculation:**

- ☒ No additional fee is required.
- ☐ Small Entity.
- ☐ An extension fee in an amount of \$\_\_\_\_\_ for a \_\_\_\_\_-month extension of time under 37 C.F.R. § 1.136(a).
- ☐ A petition or processing fee in an amount of \$\_\_\_\_\_ under 37 C.F.R. § 1.17(\_\_\_\_\_).
- ☐ An additional filing fee has been calculated as shown below:

					Small Entity			Not a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$9=			x \$18=	
Indep.		Minus			x 43=			x \$86=	
First Presentation of Multiple Dep. Claim					+\$145=			+\$290=	
					Total	\$		Total	\$

**Fee payment:**

- ☐ A check in the amount of \$\_\_\_\_\_ to cover the above-identified fee(s) is enclosed.
- ☐ Please charge Deposit Account No. 23-1925 in the amount of \$\_\_\_\_\_. A copy of this Transmittal is enclosed for this purpose.
- ☐ Payment by credit card in the amount of \$\_\_\_\_\_ (Form PTO-2038 is attached).
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

June 28, 2004  
Date

Respectfully submitted,  
Lawrence A. Steward  
Lawrence A. Steward (Reg. No. 32,309)

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on



June 28, 2004

Date of Deposit

*Carolyn Beason-Wright*

Carolyn Beason-Wright

Our Case No.: 8627/487 (PA-5391)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Constantin Cope, et al.

Serial No.: 10/813,806

Filing Date: March 31, 2004

For: BLOODLESS PERCUTANEOUS  
INSERTION SYSTEM

Examiner: Unknown

Group Art Unit No.: 3762

**INFORMATION DISCLOSURE STATEMENT**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Forms PTO/SB/08A and PTO/SB/08B be considered

by the Examiner and made of record. Copies of the documents listed on form PTO/SB/08B required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. In accordance with OG Notice 1276 OG 55 dated 5 August 2003, copies of the documents listed on form PTO/SB/08A are not enclosed.

The references now cited are the following:


No.	Date	Name
5,122,121	06/16/1992	Sos et al.
5,395,347	03/07/1995	Blecher et al.
5,407,434	04/18/1995	Gross
5,772,607	06/30/1998	Magam
5,984,895	11/16/1999	Padilla et al.
"Pulse-Vu Needle, New Design for Arterial Entry," <i>AngioDynamics</i> , Division of E-Z-EM, Inc., Queensbury, NY, 1994		
"Sos Bloodless Entry Needle, Unique Closed System Minimizes Physician Contact with Blood," <i>AngioDynamics</i> , Division of E-Z-EM, Inc., Glens Falls, NY, 1991		

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



---

Lawrence A. Steward  
Registration No. 32,309  
Attorney for Applicant(s)

LAS/cbw  
Enclosures: Form PTO/SB/08A  
Form PTO/SB/08B  
Copy of References (2)

BRINKS HOFER GILSON & LIONE  
One Indiana Square, Suite 1600  
Indianapolis, IN 46204  
(317) 636-0886



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>	<b>10/813,806</b>	
			<b>Filing Date</b>	<b>March 31, 2004</b>	
			<b>First Named Inventor</b>	<b>Constantin Cope, et al.</b>	
			<b>Group Art Unit</b>	<b>3762</b>	
			<b>Examiner Name</b>	<b>Unknown</b>	
<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>2</b>	<b>Attorney Docket Number</b>	<b>8627/487 (PA-5391)</b>

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	5,122,121		Sos et al.	06/16/1992	
	2	5,395,347		Blecher et al.	03/07/1995	
	3	5,407,434		Gross	04/18/1995	
	4	5,772,607		Magram	06/30/1998	
	5	5,984,895		Padilla et al.	11/16/1999	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

